Inhaled insulin could be a better option than injections or pumps for some patients with type 1 diabetes, a new clinical trial shows. Patients using inhaled insulin (Afrezza) plus long-lasting insulin degludec injections had better control over their blood sugar than those assigned to receive usual care, researchers report. About 21% of those on inhaled insulin had a hemoglobin A1C improvement of greater than 0.5% during the study, compared with 5% of those on standard care, results show. The clinical trial’s results “will impact diabetes management by providing health care Read More